LANDMARK research that revealed the cardiovascular benefits of empagliflozin2 (Jardiance by Boehringer Ingelheim) in people with type 2 diabetes and established cardiovascular disease has resulted in new guidelines recommending the product class.
Sodium glucose cotransporter 2 (SGLT2) class of medicines, which inhibit reabsorption of glucose in the kidney, now have a specific role described in new guidelines by the National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand.
CLICK HERE for the guidelines.
The above article was sent to subscribers in Pharmacy Daily's issue from 03 Aug 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Aug 18
